Benjamin Noll

发表

Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.

Sunita K. C. Basnet, Shudong Wang, P. Li, 2017, European journal of medicinal chemistry.

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia

Shudong Wang, F. Lam, R. Milne, 2018, Investigational New Drugs.

Sulfonamide-based inhibitors of biotin protein ligase as new antibiotic leads.

G. Booker, M. Wilce, J. Bruning, 2019, ACS chemical biology.

Discovery of N-phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine derivatives as potent Mnk2 inhibitors: design, synthesis, SAR analysis, and evaluation of in vitro anti-leukaemic activity.

Sunita K. C. Basnet, Shudong Wang, Laychiluh B Mekonnen, 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).

Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists.

Shane M. Wilkinson, M. Kassiou, Shudong Wang, 2017, European journal of medicinal chemistry.

Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.

C. Midgley, Shudong Wang, Xiangrui Liu, 2014, Journal of Medicinal Chemistry.

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin‐dependent kinases 4 and 6 as anticancer agents

Shudong Wang, F. Lam, Malika Kumarasiri, 2018, British journal of pharmacology.

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Sunita K. C. Basnet, Shudong Wang, F. Lam, 2017, Journal of medicinal chemistry.

A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.

C. Ricciardelli, N. Lokman, Shudong Wang, 2020, Gynecologic oncology.

Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.

Shudong Wang, Laychiluh B Mekonnen, Manjun Li, 2021, European journal of medicinal chemistry.

Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition

Shudong Wang, Mingfeng Yu, S. Islam, 2023, Cancers.

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia

Sunita K. C. Basnet, Shudong Wang, J. Lenjisa, 2022, Cancers.

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

J. Baell, G. McArthur, Xu Dong Zhang, 2016, Oncotarget.

Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation.

Shudong Wang, Manjun Li, Mingfeng Yu, 2021, European journal of medicinal chemistry.

Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML

I. Lewis, L. To, Shudong Wang, 2015 .

Selective inhibition of CDK9 in triple negative breast cancer

Zoya Kikhtyak, Benjamin Noll, Van T. M. Nguyen, 2023, Oncogene.

Discovery and Pharmacological Characterisation of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents Running Title Highly Selective CDK 4 / 6 Inhibitors as Anticancer Agents

Shudong Wang, F. Lam, Malika Kumarasiri, 2017 .